ERNA Ernexa Therapeutics Inc.
Healthcare$11.43-4.67%ClosedMarket Cap: $3.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.38
P/S
0.00
EV/EBITDA
0.36
DCF Value
$1.88
FCF Yield
-192.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-263.7%
ROA
-108.0%
ROIC
-138.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-3.5M | $-5.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-2.1M | $-1.5M | $— | — |
| FY null | $0.00 | NaN% | $-9.3M | $-14.1M | $— | — |
| Q3 null | $0.00 | NaN% | $-2.0M | $-1.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-2.5M | $-3.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-2.7M | $-8.2M | $— | — |
| Q4 null | $1.0K | 100.0% | $-2.7M | $-5.8M | $— | — |
| FY null | $582.0K | 83.5% | $-15.7M | $-44.5M | $— | — |
| Q3 null | $487.0K | 112.3% | $-2.3M | $-26.6M | $— | — |
| Q2 null | $47.0K | -102.1% | $-4.9M | $-5.5M | $— | — |
| Q1 null | $47.0K | -1180.9% | $-5.8M | $-6.6M | $— | — |
| Q4 2023 | $17.0K | -288.2% | $-5.8M | $-6.2M | $-1.14 | — |